{"id":1044,"date":"2026-05-18T17:30:53","date_gmt":"2026-05-18T14:30:53","guid":{"rendered":"https:\/\/life-peptide.com\/?post_type=product&#038;p=1044"},"modified":"2026-07-20T17:25:28","modified_gmt":"2026-07-20T14:25:28","slug":"cagrilintide-5-mg","status":"publish","type":"product","link":"https:\/\/life-peptide.com\/es\/product\/cagrilintide-5-mg\/","title":{"rendered":"Cagrilintide 5 mg"},"content":{"rendered":"<p>Cagrilintide is a <strong>long-acting analogue of amylin<\/strong>, a naturally occurring peptide hormone that is co-secreted with insulin by pancreatic \u03b2-cells following food intake.<\/p>\n<p>Unlike <a href=\"https:\/\/life-peptide.com\/es\/product\/semaglutide-10-mg\/\">Semaglutida<\/a>, <a href=\"https:\/\/life-peptide.com\/es\/product\/tirzepatide-10-mg\/\">Tirzepatida<\/a> y <a href=\"https:\/\/life-peptide.com\/es\/product\/retatrutide-10-mg\/\">Retatrutida<\/a>, which act primarily through incretin pathways, Cagrilintide targets <strong>amylin and calcitonin receptor systems<\/strong>, introducing a complementary mechanism for regulating appetite and energy balance. This distinct pharmacology has made it one of the most important investigational compounds in modern metabolic peptide research.<\/p>\n<p>Because its mechanism differs fundamentally from GLP-1 receptor agonists, Cagrilintide has become an important molecule for researchers investigating combination therapies that engage multiple appetite-regulating pathways simultaneously.<\/p>\n<hr \/>\n<h4><strong>Why Cagrilintide matters in metabolic research<\/strong><\/h4>\n<p>Cagrilintide represents one of the first long-acting amylin analogues capable of maintaining sustained receptor activation through once-weekly administration in published clinical research.<\/p>\n<p>Its unique mechanism has made it an important research tool for studying:<\/p>\n<ul>\n<li><strong>appetite regulation<\/strong><\/li>\n<li><strong>satiety signalling<\/strong><\/li>\n<li><strong>gastric emptying<\/strong><\/li>\n<li><strong>energy balance<\/strong><\/li>\n<li><strong>body-weight regulation<\/strong><\/li>\n<li><strong>amylin biology<\/strong><\/li>\n<li><strong>combination therapy with GLP-1 receptor agonists<\/strong><\/li>\n<\/ul>\n<p>Rather than replacing GLP-1 agonists, Cagrilintide is frequently investigated as a <strong>complementary metabolic peptide<\/strong> because it activates physiological pathways that differ from incretin signalling alone.<\/p>\n<hr \/>\n<h4><strong>How Cagrilintide works<\/strong><\/h4>\n<p>Cagrilintide primarily <strong>activates amylin receptors<\/strong>, with additional activity through calcitonin receptor complexes.<\/p>\n<p>Amylin is released naturally alongside insulin after meals and contributes to physiological regulation of:<\/p>\n<ul>\n<li><strong>satiety<\/strong><\/li>\n<li><strong>gastric emptying<\/strong><\/li>\n<li><strong>glucagon secretion<\/strong><\/li>\n<li><strong>food intake<\/strong><\/li>\n<\/ul>\n<p>Unlike GLP-1 receptor agonists, which primarily amplify incretin signalling, Cagrilintide reproduces key aspects of endogenous amylin physiology. This complementary mechanism explains why it has become <strong>a major focus of combination research<\/strong> with Semaglutide and other incretin-based peptides.<\/p>\n<hr \/>\n<h4><strong>Published clinical findings on Cagrilintide<\/strong><\/h4>\n<p>Human clinical studies have demonstrated that investigational Cagrilintide produces <strong>dose-dependent reductions in body weight<\/strong> together with improvements in <strong>appetite control and satiety<\/strong>. In the Phase 2 dose-finding trial published in The Lancet, once-weekly Cagrilintide produced significantly greater body-weight reduction than placebo and was generally well tolerated across the investigated dose range.<\/p>\n<p>One of the most important developments in subsequent research has been the investigation of Cagrilintide in combination with Semaglutide. Rather than acting on the same receptor, the two molecules <strong>engage complementary biological pathways<\/strong>, allowing researchers to evaluate whether combined amylin and GLP-1 signalling produces <strong>broader metabolic effects than either mechanism alone<\/strong>. Later combination studies supported this rationale and helped establish Cagrilintide as a leading partner for GLP-1-based metabolic research.<\/p>\n<hr \/>\n<h4><strong>Resultados publicados de seguridad y tolerabilidad<\/strong><\/h4>\n<p>Published clinical studies indicate that the most frequently reported adverse events with investigational Cagrilintide are gastrointestinal, including <strong>nausea, vomiting and gastrointestinal discomfort<\/strong>. Similar to GLP-1 receptor agonists, these events were generally <strong>relacionado con la dosis<\/strong> and occurred most often during dose escalation. Most were reported as mild to moderate in severity.<\/p>\n<p>Because Cagrilintide is commonly investigated alongside GLP-1 receptor agonists, tolerability remains an important component of ongoing clinical research. Published studies therefore evaluate not only efficacy, but also the balance between appetite-related outcomes and gastrointestinal tolerability.<\/p>\n<hr \/>\n<h4><strong>Published dosing schedules used in Cagrilintide research<\/strong><\/h4>\n<p>Published clinical studies generally investigated <strong>once-weekly administration with gradual dose escalation<\/strong> rather than immediate initiation at higher maintenance doses. Phase 2 obesity studies evaluated several dose levels to characterise both efficacy and tolerability across the dose range.<\/p>\n<p>More recent combination studies evaluating Cagrilintide together with Semaglutide have continued to use structured escalation schedules similar to those employed throughout the broader incretin field. These published schedules are presented as summaries of clinical trial design and should not be interpreted as instructions for use.<\/p>\n<hr \/>\n<h4><strong>Cagrilintide vs Semaglutide vs Tirzepatide<\/strong><\/h4>\n<p><strong>Cagrilintida<\/strong><\/p>\n<ul>\n<li><strong>Long-acting amylin analogue<\/strong><\/li>\n<li>Amylin \/ calcitonin receptor activity<\/li>\n<li>Complementary to incretin signalling<\/li>\n<li>Frequently investigated in combination with GLP-1 agonists<\/li>\n<\/ul>\n<p><strong>Semaglutida<\/strong><\/p>\n<ul>\n<li><strong>GLP-1 receptor agonist<\/strong><\/li>\n<li>Foundation of GLP-1 research<\/li>\n<li>Extensive clinical evidence<\/li>\n<\/ul>\n<p><strong>Tirzepatida<\/strong><\/p>\n<ul>\n<li><strong>GLP-1 \/ GIP dual agonist<\/strong><\/li>\n<li>Expanded incretin signalling<\/li>\n<li>Often compared with combination strategies involving Cagrilintide<\/li>\n<\/ul>\n<hr \/>\n<h4><strong>Caracter\u00edsticas del producto<\/strong><\/h4>\n<p>Aplicaci\u00f3n: investigaci\u00f3n de laboratorio y an\u00e1lisis<br \/>\nUso restringido: no apto para consumo humano; no apto para uso m\u00e9dico, veterinario o cosm\u00e9tico<br \/>\nProducido en instalaciones que cumplen con GMP bajo estrictos protocolos de control de calidad.<br \/>\nCada lote se somete a pruebas de laboratorio exhaustivas despu\u00e9s de la producci\u00f3n (puede encontrar el Certificado de An\u00e1lisis debajo de las im\u00e1genes del producto).<br \/>\nLiofilizado (liofilizado) para m\u00e1xima estabilidad y vida \u00fatil prolongada.<br \/>\nSellado en viales est\u00e9riles, listo para la reconstituci\u00f3n.<br \/>\nPurity: \u2265 98.6% (HPLC)<br \/>\nApariencia: polvo blanco liofilizado<br \/>\nF\u00f3rmula molecular: C<sub>194<\/sub>H<sub>312<\/sub>N<sub>54<\/sub>O<sub>59<\/sub> S<sub>2<\/sub><br \/>\nMolecular weight: 4409.01<br \/>\nSequence: {diacid-C20-\u03b3-Glu}KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP-NH2<br \/>\nStorage: unopened lyophilized vials are best stored refrigerated at 2\u20138\u00b0C, which is the storage method confirmed by our manufacturing partner and suitable for up to 24 months. Refrigeration is preferred because it minimizes unnecessary freeze\u2013thaw cycles during routine handling. If substantially longer-term storage is required, unopened lyophilized vials may also be kept frozen. Once reconstituted, always store at 2\u20138\u00b0C and do not freeze.<\/p>\n<hr \/>\n<h4><strong>Reconstituci\u00f3n y manipulaci\u00f3n<\/strong><\/h4>\n<p>Cagrilintide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with <a href=\"https:\/\/life-peptide.com\/es\/product\/bac-10-ml\/\">agua bacteriost\u00e1tica<\/a> Antes de usar. Los p\u00e9ptidos de la clase GLP-1 a veces tardan en disolverse y requieren una reconstituci\u00f3n muy suave para evitar la formaci\u00f3n de espuma o que queden ligeramente turbios.<\/p>\n<p>Para otras gu\u00edas sobre selecci\u00f3n de solventes, planificaci\u00f3n de concentraciones y almacenamiento, consulte el completo <a href=\"https:\/\/life-peptide.com\/es\/reconstitution-of-peptides\/\">Gu\u00eda de Reconstituci\u00f3n de P\u00e9ptidos<\/a> y <a href=\"https:\/\/life-peptide.com\/es\/calculator\/\">Calculadora de Reconstituci\u00f3n<\/a>.<\/p>\n<hr \/>\n<h4>Estudios clave publicados<\/h4>\n<ul>\n<li>Lau DCW et al.\u00a0<em>Once-weekly Cagrilintide for Weight Management in People with Overweight or Obesity. The Lancet<\/em>. 2021.The landmark Phase 2 dose-finding study demonstrating significant dose-dependent body-weight reduction and establishing Cagrilintide as the leading long-acting amylin analogue for metabolic research.<\/li>\n<li>Kruse T et al.\u00a0<em>Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry.<\/em> 2021.The foundational medicinal chemistry publication describing the molecular design, receptor pharmacology and development strategy behind Cagrilintide as a long-acting amylin analogue.<\/li>\n<li>Frias JP et al.\u00a0<em>Efficacy and Safety of Co-administered Cagrilintide with Semaglutide in Type 2 Diabetes. The Lancet.<\/em> 2023.The pivotal clinical study evaluating combined amylin and GLP-1 receptor agonism, providing the scientific rationale for subsequent CagriSema research.<\/li>\n<li>D&#8217;Ascanio AM et al.\u00a0<em>Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiology in Review.<\/em> 2023.A comprehensive review summarising pharmacology, mechanism of action, clinical development and the role of Cagrilintide within modern metabolic research.<\/li>\n<\/ul>\n<hr \/>\n<h4><strong>Preguntas frecuentes<\/strong><\/h4>\n<p><strong>What is Cagrilintide?<\/strong><\/p>\n<p>Cagrilintide is a long-acting analogue of the hormone amylin, designed to reproduce and prolong physiological amylin signalling. Unlike GLP-1 receptor agonists, it primarily targets amylin receptor pathways, making it one of the leading investigational peptides for studying appetite regulation and satiety biology.<\/p>\n<p><strong>How does Cagrilintide work?<\/strong><\/p>\n<p>Cagrilintide activates amylin receptor systems involved in satiety, gastric emptying and energy balance. Its mechanism complements rather than duplicates GLP-1 receptor signalling, which is why it is frequently investigated alongside GLP-1 agonists such as Semaglutide.<\/p>\n<p><strong>Why is Cagrilintide often combined with Semaglutide?<\/strong><\/p>\n<p>Cagrilintide and Semaglutide act through different biological pathways. Cagrilintide primarily targets amylin receptor signalling, while Semaglutide activates the GLP-1 receptor. Published clinical research has investigated whether combining these complementary mechanisms can produce broader metabolic effects than either pathway alone.<\/p>\n<p><strong>How is Cagrilintide different from GLP-1 receptor agonists?<\/strong><\/p>\n<p>Unlike Semaglutide, Tirzepatide and Retatrutide, Cagrilintide is not an incretin receptor agonist. It is a long-acting amylin analogue with a distinct mechanism of action, making it an important addition to metabolic research rather than simply another GLP-1-derived peptide.<\/p>\n<p><strong>What research areas commonly investigate Cagrilintide?<\/strong><\/p>\n<p>Published studies have investigated Cagrilintide in relation to appetite regulation, satiety signalling, body-weight outcomes, gastric emptying, energy balance and combination therapy with GLP-1 receptor agonists. Its unique pharmacology has made it one of the leading molecules in amylin-based metabolic research.<\/p>\n<p><strong>\u00bfEst\u00e1 este producto destinado al uso humano?<\/strong><\/p>\n<p>No. Cagrilintide supplied by LIFE Peptide is provided strictly for laboratory research and analytical use. It is not intended for human consumption, diagnosis, treatment or prevention of disease. Any discussion of published clinical studies on this page is included solely to summarise the current scientific literature surrounding the Cagrilintide molecule.<\/p>\n<hr \/>\n<h4><strong>Contexto de investigaci\u00f3n relacionado<\/strong><\/h4>\n<p>Cagrilintide belongs to the amylin analogue class within metabolic research.<br \/>\nFor comparative frameworks:<br \/>\n\u2022 GLP-1 receptor agonists (e.g., <a href=\"https:\/\/life-peptide.com\/es\/product\/semaglutide-10-mg\/\">Semaglutida<\/a>)<br \/>\n\u2022 Dual agonists (e.g., <a href=\"https:\/\/life-peptide.com\/es\/product\/tirzepatide-10-mg\/\">Tirzepatida<\/a>)<br \/>\n\u2022 Combination models (e.g., CagriSema research frameworks)<br \/>\nFor broader mechanism comparison, see the <a href=\"\/es\/glp-1-metabolic-research-guide\/\">Gu\u00eda de investigaci\u00f3n metab\u00f3lica de GLP-1<\/a> and explore the <a href=\"\/es\/category\/peptidos-de-investigacion-metabolica\/\">Metabolic research category<\/a> for related compounds.<\/p>\n<hr \/>\n<p><strong>NOTA<\/strong>: Esto es solo para fines de referencia educativa y no constituye asesoramiento m\u00e9dico.<\/p>\n<p><strong>Descargo de responsabilidad<\/strong><br \/>\nEste producto se vende \u00fanicamente para fines de investigaci\u00f3n. No est\u00e1 destinado a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. El comprador asume toda la responsabilidad por su manipulaci\u00f3n y uso adecuados.<\/p>","protected":false},"excerpt":{"rendered":"<p>Cagrilintide 5 mg is a research-grade long-acting amylin analogue supplied in lyophilised form for laboratory use. It has become one of the leading investigational peptides for metabolic research, particularly in studies of appetite regulation, satiety signalling and combination approaches with GLP-1 receptor agonists such as Semaglutide.<\/p>\n<p>||<\/p>\n<p>Purity \u226598% | EU shipping from \u20ac5 | Free shipping upgrades available | Card payments accepted<\/p>","protected":false},"featured_media":1045,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[19],"product_tag":[152,249,257,288,247,153,252,159,246],"class_list":["post-1044","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic-research-peptides","product_tag-amylin-analogue","product_tag-appetite-pathways","product_tag-appetite-regulation","product_tag-buy-cagrilintide","product_tag-metabolic-peptide","product_tag-metabolic-research","product_tag-obesity-research","product_tag-satiety-signaling","product_tag-weight-loss-peptide","first","instock","taxable","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product\/1044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/comments?post=1044"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/media\/1045"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/media?parent=1044"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product_brand?post=1044"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product_cat?post=1044"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/life-peptide.com\/es\/wp-json\/wp\/v2\/product_tag?post=1044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}